Taikang Asset Management (Hong Kong) CO LTD Zai Lab LTD Transaction History

Taikang Asset Management (Hong Kong) CO LTD

$937 Million
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$22.28 - $38.71 $1.77 Million - $3.08 Million	79,500 Added 530.0%	94,500 $2.9 Million
Q2 2021 Aug 10, 2021	BUY	$125.11 - $180.0 $1.88 Million - $2.7 Million	15,000 New	15,000 $2.66 Million

Others Institutions Holding ZLAB

# of Institutions

123

Shares Held

46.7M

Call Options Held

223K

Put Options Held

588K

Janus Henderson Group PLC London, X0

8.76M
Shares

$228 Million
0.11% of portfolio
Wellington Management Group LLP Boston, MA

8.44M
Shares

$220 Million
0.04% of portfolio
Capital World Investors Los Angeles, CA

6.44M
Shares

$168 Million
0.02% of portfolio
Viking Global Investors LP

1.95M
Shares

$50.8 Million
0.18% of portfolio
Bamco Inc New York, NY

1.91M
Shares

$49.7 Million
0.13% of portfolio

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.55B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Taikang Asset Management (Hong Kong) CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Taikang Asset Management (Hong Kong) CO LTD with notifications on news.

Account